

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 62307

Manuscript Type: ORIGINAL ARTICLE

Observational Study

Exploration of Nucleos(t)ide analogues cessation in chronic hepatitis B patients with hepatitis B e antigen loss

Xue Y *et al.* NAs cessation in HBeAg loss patients

Abstract

BACKGROUND

Nucleos(t)ide analogs (NAs) cessation in chronic hepatitis B (CHB) patients remains a matter of debate in clinical practice. Current guidelines recommend that patients with hepatitis B e antigen (HBeAg) seroconversion discontinue NAs after relatively long-term consolidation therapy. However, many patients fail to achieve HBeAg seroconversion after the long-term loss of HBeAg even if hepatitis B surface antigen

Match Overview

Match Number	Source	Words	Similarity
1	Crossref	123 words	4%
	"Abstracts of the 26th Annual Conference of APASL, February 15–19, 2017, Shanghai, China"; Hepatology International		
2	Internet	73 words	2%
	crawled on 17-Mar-2019 onlinelibrary.wiley.com		
3	Crossref	52 words	2%
	"Abstracts of the 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japan"; Hepatology International		
4	Crossref	43 words	1%
	"Posters (Abstracts 301–2389)"; Hepatology, 2018		
5	Internet	35 words	1%
	crawled on 28-Nov-2018 aasidpubs.onlinelibrary.wiley.com		
6	Internet	29 words	1%
	crawled on 23-Sep-2020 pesquisa.bvsalud.org		
7	Internet	24 words	1%
	crawled on 08-Dec-2020 www.researchsquare.com		
8	Internet	23 words	1%
	crawled on 25-Dec-2019 www.medscape.com		



ALL

IMAGES

VIDEOS

40,200 Results

Any time ▾

Discontinuation of **nucleos (t)ide analogues (NA)** therapy in **patients with chronic hepatitis B** may lead to functional cure, defined as **HBsAg loss**. However, previous studies have highlighted contradictory findings because of widely ranging rates of relapse and sometimes dangerous flares. What are the new findings?

Author: Kin Seng Liem, Scott Fung, David K Wong, Colina Yim, Seham Noureldin, Jiayun Chen, Jordan J Feld, Jo...

Cited by: 16

Publish Year: 2019

[Limited sustained response after stopping nucleos\(t\)ide ...](#)

[BMJ gut.bmj.com/content/68/12/2206](https://www.bmj.com/content/68/12/2206)

Was this helpful?



[Cessation of nucleos\(t\)ide analogues for patients with ...](#)

<https://journals.lww.com/jcma/Fulltext/2020/06000/...>

Long-term nucleos(t)ide analogue (NA) therapy for patients with chronic hepatitis B (CHB) is safe and well tolerated; achieves potent viral suppression, regression of liver fibrosis and cirrhosis; and reduces the incidence of liver-related adverse outcomes, such as complications of cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). 1 The ideal treatment endpoint for CHB is ...

[When to stop nucleos\(t\)ide analogues treatment for chronic ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064065>

Jun 21, 2014 · Core tip: Introduction of nucleos(t)ide analogues (NAs) for oral antiviral therapy has dramatically improved the clinical outcome in patients with chronic hepatitis B (CHB). While attention has been drawn to whether antiviral treatment with NAs can be a finite therapy in patients with CHB, current guidelines for stopping NA therapy seems to be inadequate in terms of off-treatment durability in both hepatitis ...

Cited by: 6

Author: Wonseok Kang, Jun Yong Park

Publish Year: 2014

[Stopping long-term treatment with nucleos\(t\)ide analogues ...](#)

<https://pubmed.ncbi.nlm.nih.gov/29427489>

53,600 Results Any time ▾

Systematic review: cessation of long-term nucleos(t)ide ...

<https://pubmed.ncbi.nlm.nih.gov/26151841>

Background: It has been debated whether finite **nucleos(t)ide analogue** therapy is feasible in HBeAg-negative **chronic hepatitis B**. Aim: To review this issue systematically. Methods: Using text terms HBsAg and various **nucleos(t)ide analogues**, PubMed was searched between 1995 and 2014 to find studies on therapy >6 months in adult HBeAg-negative **chronic hepatitis B patients** with off-therapy follow ...

Cited by: 103 **Author:** M.-L. Chang, Y.-F. Liaw, S. J. Hadziyannis
Publish Year: 2015

The Role of Hepatitis B Surface Antigen in Nucleos(t)ide ...

<https://www.ncbi.nlm.nih.gov/pubmed/30561829>

In actual clinical practice, infinite **nucleos(t)ide analogues** (NAs) treatment for **chronic hepatitis B virus** (HBV) infection is unrealistic. The most commonly used endpoint is suppression of HBV DNA to undetectable levels with normalization of alanine aminotransferase.

Cited by: 57 **Author:** Jiaye Liu, Jiaye Liu, Tao Li, Li Zhang, Li Zha...
Publish Year: 2019

Stopping nucleos(t)ide analogue treatment in Caucasian ...

<https://www.ncbi.nlm.nih.gov/pubmed/29498078>

BACKGROUND: **Stopping nucleos(t)ide analogues** (NA) after **hepatitis B e antigen** (HBeAg) seroconversion is associated with high relapse rates in Asian patients, but data in Caucasian cohorts are scarce. Clinical course, outcomes and immunological aspects of **chronic hepatitis B** infections differ substantially between distinct ethnicities.

Cited by: 19 **Author:** S Van Hees, S Bourgeois, H Van Vlierbergh...
Publish Year: 2018

[PDF] Nucleos(t)ide analogues in patients with chronic hepatitis ...

<https://gut.bmj.com/content/gutjnl/68/12/2105.full.pdf>

review: **cessation of long-term nucleos(t)ide analogue** therapy in **patients with hepatitis B e antigen-negative chronic hepatitis B**. Aliment Pharmacol Ther 2015;42:243–57. 4 Papatheodoridis G, Vlachogiannakos I, Cholongitas E, et al. Discontinuation of oral antivirals in **chronic hepatitis B**: a systematic review. Hepatology 2016;63:1481–92.

Cited by: 2 **Author:** Jia-Hong Kao, Thomas Berg
Publish Year: 2019

Hepatitis B flare after cessation of nucleos(t)ide ...

<https://pubmed.ncbi.nlm.nih.gov/32810321>

Abstract. Finite **nucleos (t)ide analogue** (Nuc) therapy in HBV suppressed **hepatitis B e antigen** (HBeAg)-negative **patients with chronic hepatitis B** may substantially increase **hepatitis B** surface antigen (HBsAg) loss rate after **cessation** of therapy, in which "no retreatment" is a strong predictor for HBsAg loss. However, the main safety concern of no retreatment is hepatitis flare leading to hepatic ...

Cited by: 1 **Author:** Yun-Fan Liaw
Publish Year: 2021

Hepatitis B virus-specific T cell responses after stopping ...

<https://pubmed.ncbi.nlm.nih.gov/29758333>

Background & aims: Treatment with **nucleos(t)ide analogues** (NA) leads to **hepatitis B virus** (HBV) DNA suppression in most **patients with chronic hepatitis B** (CHB), but HBV surface antigen (HBsAg) loss rates are low. Upon NA discontinuation, HBV DNA can return rapidly with ensuing alanine aminotransferase flares and induction of cytokines.

Cited by: 34 **Author:** Franziska Rinker, Christine L. Zimmer, Chris...
Publish Year: 2018

Persistence and adherence to nucleos(t)ide analogues in ...

<https://www.ncbi.nlm.nih.gov/pubmed/31688309>

Oct 30, 2019 · BACKGROUND: Adherence and persistence to long-term therapy with **nucleos(t)ides analogues** are crucial to the outcome of treatment in **chronic hepatitis B**. Our aim was to determine the persistence and adherence rates to **nucleos(t)ides analogues in chronic hepatitis B patients** under maintenance therapy and to identify relative to prediction of ...

Cited by: 1 **Author:** Spilios Manolakopoulos, Athanasia Striki, V...
Publish Year: 2020

Varying 10-year off-treatment responses to nucleos(t)ide ...

<https://www.ncbi.nlm.nih.gov/pubmed/30098114>

1. J Dig Dis. 2018 Sep;19(9):561-571. doi: 10.1111/1751-2980.12654. Epub 2018 Sep 19. Varying 10-year off-treatment responses to **nucleos(t)ide analogues in patients with chronic hepatitis B** according to their pretreatment **hepatitis B e antigen** status.

Cited by: 7 **Author:** Feng Liu, Zhi Rong Liu, Tao Li, You De Liu, ...
Publish Year: 2018

Hepatitis B Flare After Cessation of Nucleos(t)ide ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.31525?af=R>

Click on the article title to read more.

Role of serum HBV RNA and hepatitis B surface antigen ...

<https://europepmc.org/article/MED/32759300>

Nucleos(t)ide analogue (NUC) treatment was discontinued in non-cirrhotic **patients with chronic HBV** with serum HBsAg <200 IU/mL and fulfilling internationally recommended criteria for treatment **cessation**. **Patients** were monitored till 48 weeks with baseline and serial measurements of serum HBsAg, HBV RNA and **hepatitis B** core-related antigen.

ALL

IMAGES

VIDEOS

52,000 Results

Any time ▾

Open links in new tab



Long-term outcomes after nucleos(t)ide analogues ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850530>

CHB may present either as **hepatitis B e antigen** (HBeAg)-positive or HBeAg-negative. The prevalence of **HBeAg-negative CHB** has been increasing over the last decade and represents the majority of cases in many areas. The strategy of long-term treatment with **nucleos(t)ide analogues** (NUCs) is necessary for HBeAg-positive **patients**. Unlike interferons, which are administered for predefined durations of time ...

Cited by: 21

Author: Dengming He, Shimin Guo, Wen Chen, Xian...

Publish Year: 2013

The Role of Hepatitis B Surface Antigen in Nucleos(t)ide ...

<https://pubmed.ncbi.nlm.nih.gov/30561829>

In actual clinical practice, infinite **nucleos(t)ide analogues** (NAs) treatment for **chronic hepatitis B** virus (HBV) infection is unrealistic. The most commonly used endpoint is suppression of HBV DNA to undetectable levels with normalization of alanine aminotransferase. However, this criterion for ces ...

Cited by: 58

Author: Jiaye Liu, Jiaye Liu, Tao Li, Li Zhang, Li Zha...

Publish Year: 2019

Limited sustained response after stopping nucleos(t)ide ...

<https://www.ncbi.nlm.nih.gov/pubmed/31462554>

1. Gut. 2019 Dec;68(12):2206-2213. doi: 10.1136/gutjnl-2019-318981. Epub 2019 Aug 28. Limited sustained response after stopping **nucleos(t)ide analogues** in **patients** with **chronic hepatitis B**: results from a randomised controlled trial (Toronto STOP study).

Cited by: 21

Author: Kin Seng Liem, Scott Fung, David K Wong, ...

Publish Year: 2019

Hepatitis B virus-specific T cell responses after stopping ...

<https://pubmed.ncbi.nlm.nih.gov/29758333>

Background & aims: Treatment with **nucleos(t)ide analogues** (NA) leads to **hepatitis B** virus (HBV) DNA suppression in most **patients** with **chronic hepatitis B** (CHB), but HBV surface **antigen** (HBsAg) **loss** rates are low. Upon NA discontinuation, HBV DNA can return rapidly with ensuing alanine aminotransferase flares and induction of cytokines.

Cited by: 52

Author: Franziska Rinker, Christine L. Zimmer, Chris...

Publish Year: 2018

Incidence and predictors of hepatitis B surface antigen ...

<https://pubmed.ncbi.nlm.nih.gov/29108132>

Search Tools

Turn off Hover Translation (关闭取词)